Aortic distensibility in alkaptonuria.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
08 2020
Historique:
received: 09 12 2019
revised: 11 05 2020
accepted: 13 05 2020
pubmed: 30 5 2020
medline: 4 5 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

Alkaptonuria (AKU) is a rare inherited disorder of tyrosine metabolism resulting in an accumulation of homogentisic acid oxidation products in the joints and cardiovascular system. Aortic distensibility may be a non-invasive indicator of cardiovascular complications. Descending thoracic aortic distensibility in alkaptonuria has not been studied. Patients diagnosed with alkaptonuria underwent Magnetic Resonance Imaging (MRI) and gated non-contrast and contrast-enhanced cardiovascular computed tomography. Using MRI cine images, aortic distensibility of the descending thoracic aorta was determined. Seventy-six patients with alkaptonuria were imaged. When compared to literature normal values, aortic distensibility in AKU was impaired (5.2 vs 6.2 × 10 Patients with alkaptonuria have impaired aortic distensibility, which is likely an early marker for reduced cardiovascular health. Variables such as age, hypertension, hyperlipidemia, and aortic and coronary calcification were associated with impaired distensibility.

Identifiants

pubmed: 32466960
pii: S1096-7192(20)30120-7
doi: 10.1016/j.ymgme.2020.05.006
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-296

Informations de copyright

Published by Elsevier Inc.

Auteurs

Rashmi Thimmapuram (R)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

W Patricia Bandettini (WP)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

Sujata M Shanbhag (SM)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

Jeannie H Yu (JH)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America; Veterans Affairs Medical Center, Long Beach, CA, United States of America.

Kevin J O'Brien (KJ)

National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States of America.

William A Gahl (WA)

National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States of America.

Wendy J Introne (WJ)

National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States of America.

Marcus Y Chen (MY)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America. Electronic address: marcus.chen@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH